Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2071250075) titled 'A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease' on Sept. 29.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose
Primary Sponsor: Sakamoto Takehiko
Condition:
Crohn Disease
Intervention:
1. Experimental: Induction Study 1: Icotrokinra Dose 1
Participants will receive Icotrokinra dose 1 in Induction Study 1 up to Week 12.Subsequent treatment will be determined by the participants response status at Week 12.
Drug: Icotrokinra
Icotrokinra will be administered orally, daily.
Ot...